The DOI matches its Crossref record.
History of the Development of Rifampin
Abstract
Rifampin was developed in the Dow-Lepetit Research Laboratories (Milan, Italy) as part of an extensive program of chemical modification of the rifamycins, the natural metabolites of Nocardia mediterranei. One peculiar fact was that all of the studies leading to highly active derivatives were performed on a molecule (rifamycin B) that was itself practically inactive. The first chemical modifications led to the discovery of rifamycin SV, which was introduced in some countries for the parenteral and topical treatment of infections due to gram-positive bacteria and infections of the biliary tract. Systematic structural modifications of most of the functional groups of the rifamycin molecule were performed with the objective of finding a derivative that was active when administered orally. The understanding of structure-activity relations in the rifamycins led to the synthesis of several hydrazones of 3-formylrifamycin SV. Among them, the hydrazone with N-amino-N'-methylpiperazine (rifampin) was the most active in the oral treatment of infections in animals and, after successful clinical trials, was introduced into therapeutic use in 1968. In the intervening years, a large number of clinical and biologic studies have confirmed the important role of rifampin in therapy for tuberculosis and other selected infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
How antibiotics kill bacteria: from targets to networks
Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2333 · Cited by 2,258
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
RifamycinMode of Action, Resistance, and Biosynthesis
Floss, H. G., & Yu, T.-W. (2005) · Chemical Reviews · doi:10.1021/cr030112j · Cited by 547
Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives
Gygli, S. M., Borrell, S., Trauner, A., & Gagneux, S. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux011 · Cited by 457
Metadata
- Authors
- Sensi, P.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1983-07-01
- Volume
- 5
- Issue
- Supplement_3
- Pages
- S402-S406
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2089997464
- Cited by
- 315
- References
- 0
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: History of the Development of Rifampin. https://app.cochat.ai/papers/10.1093/clinids/5.supplement_3.s402
- The paper
- Sensi, P. (1983). History of the Development of Rifampin. Clinical Infectious Diseases. https://doi.org/10.1093/clinids/5.supplement_3.s402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.